Immunotherapy duo takes aim at tough pancreatic cancer before surgery
NCT ID NCT06060405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether giving two immunotherapy drugs, durvalumab and oleclumab, before surgery can boost the immune system's attack on pancreatic cancer. The study involves people with resectable pancreatic ductal adenocarcinoma (PDAC) who will receive the drugs in a short window before their tumor is removed. Researchers will measure changes in immune cells within the tumor to see if the treatment enhances the body's natural defenses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab and oleclumab
What this could lead to
If successful, this approach could improve immune response against pancreatic cancer, potentially leading to better outcomes after surgery.
What could go wrong
This is a small, early-phase study focused on immune markers, not survival. The drugs may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Contact